Intec Pharma (NASDAQ:NTEC) has been assigned a $15.00 target price by Oppenheimer in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 185.71% from the company’s current price.
Other research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Intec Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Maxim....More>>>